UY30575A1 - Compuestos como aptameros-dimeros y sus usos en el diagnostico y la terapia - Google Patents

Compuestos como aptameros-dimeros y sus usos en el diagnostico y la terapia

Info

Publication number
UY30575A1
UY30575A1 UY30575A UY30575A UY30575A1 UY 30575 A1 UY30575 A1 UY 30575A1 UY 30575 A UY30575 A UY 30575A UY 30575 A UY30575 A UY 30575A UY 30575 A1 UY30575 A1 UY 30575A1
Authority
UY
Uruguay
Prior art keywords
aptameros
dimeros
diagnosis
therapy
compounds
Prior art date
Application number
UY30575A
Other languages
English (en)
Inventor
Maren Hecht
Ananth Srinivasan
Andrew Stephens
Matthias Friebe
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37866215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30575(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY30575A1 publication Critical patent/UY30575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

El objeto de la presente invencion es satisfecho por composiciones de conectores peptídicos y su uso para la síntesis y el alineamiento de oligonucleotidos aptámeros en forma de dímeros. En particular, en la presente invencion se proveen composiciones de este tipo para usar como agente de diagnostico y/o terapéutico.
UY30575A 2006-09-08 2007-09-05 Compuestos como aptameros-dimeros y sus usos en el diagnostico y la terapia UY30575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06090164A EP1897886A1 (en) 2006-09-08 2006-09-08 Compounds as aptamer-dimers and their uses in diagnosis and therapy

Publications (1)

Publication Number Publication Date
UY30575A1 true UY30575A1 (es) 2008-05-02

Family

ID=37866215

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30575A UY30575A1 (es) 2006-09-08 2007-09-05 Compuestos como aptameros-dimeros y sus usos en el diagnostico y la terapia

Country Status (10)

Country Link
US (1) US20080207523A1 (es)
EP (2) EP1897886A1 (es)
JP (1) JP2010502657A (es)
AR (1) AR062697A1 (es)
CA (1) CA2662439A1 (es)
CL (1) CL2007002576A1 (es)
PE (1) PE20081369A1 (es)
TW (1) TW200812627A (es)
UY (1) UY30575A1 (es)
WO (1) WO2008028530A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542266A4 (en) 2010-03-03 2013-10-23 Somalogic Inc 4-1BB-BINDING APTAMERS AND USE THEREOF IN THE TREATMENT OF DISEASES AND DISORDERS
SG184497A1 (en) * 2010-04-12 2012-11-29 Somalogic Inc 5-position modified pyrimidines and their use
TWI497076B (zh) 2010-06-25 2015-08-21 Univ Nat Cheng Kung 適合體及ｃ－反應蛋白檢測方法
DE102010026062A1 (de) * 2010-06-30 2012-01-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Aptamer-Komplex zur Detektion eines krankhaften Gewebes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112536D0 (en) * 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
DE4339646A1 (de) * 1993-11-20 1995-05-24 Basf Ag Diacetylenverbindungen
ES2314238T3 (es) * 2002-10-08 2009-03-16 Fresenius Kabi Deutschland Gmbh Conjugados de oligosacaridos farmaceuticamente activos.

Also Published As

Publication number Publication date
WO2008028530A1 (en) 2008-03-13
EP2074137A1 (en) 2009-07-01
CL2007002576A1 (es) 2008-05-23
US20080207523A1 (en) 2008-08-28
EP1897886A1 (en) 2008-03-12
CA2662439A1 (en) 2008-03-13
JP2010502657A (ja) 2010-01-28
AR062697A1 (es) 2008-11-26
TW200812627A (en) 2008-03-16
PE20081369A1 (es) 2008-12-05

Similar Documents

Publication Publication Date Title
ECSP10010637A (es) Anticuerpos anti-factor d humanizados y sus usos
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
CR11130A (es) Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados
CR20110509A (es) Composicion farmaceutica
CL2008002787A1 (es) Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil.
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
DOP2007000016A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina.
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
BR112012011195A2 (pt) Oligonucleotídeo antissentido, composição e respectivo uso.
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
CL2007003733A1 (es) Compuestos derivados de indolin-2-ona, bencimidazol-2-ona y benzoxazol-2-ona, moduladores de serina palmitoiltransferasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 1 y 2, obesidad, aterosclerosis, hi
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
EA201170190A1 (ru) Фармацевтическая композиция, содержащая экстракт мозга свиньи
HN2010000330A (es) DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION
CL2008000318A1 (es) Compuestos derivados de n-(2,3,4,4a,5,6-hexahidro-1h-pirazino(1,2-a)quinolina-8-carbonil)bencenosulfonamida; procedimiento de preparacion; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar el cancer de vejiga, cerebro, m
CU20120081A7 (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
CL2007003223A1 (es) Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170726